Royal London Asset Management Ltd. Acquires 2,711 Shares of Cencora, Inc. (NYSE:COR)

Royal London Asset Management Ltd. raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 101,284 shares of the company's stock after buying an additional 2,711 shares during the quarter. Royal London Asset Management Ltd. owned 0.05% of Cencora worth $22,756,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of COR. Algebris UK Ltd bought a new position in Cencora during the fourth quarter worth $1,188,000. Vinva Investment Management Ltd boosted its position in shares of Cencora by 204.2% during the 4th quarter. Vinva Investment Management Ltd now owns 24,886 shares of the company's stock worth $5,592,000 after purchasing an additional 16,704 shares in the last quarter. Xponance Inc. grew its stake in shares of Cencora by 9.2% in the 4th quarter. Xponance Inc. now owns 68,295 shares of the company's stock valued at $15,345,000 after buying an additional 5,758 shares during the period. Boston Partners increased its position in Cencora by 2.6% in the 4th quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after buying an additional 125,611 shares in the last quarter. Finally, Generali Asset Management SPA SGR acquired a new position in Cencora during the 4th quarter worth approximately $6,279,000. 97.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

COR has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Wells Fargo & Company raised their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Finally, StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $280.20.

Remove Ads

Insiders Place Their Bets

In related news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,970 shares of company stock valued at $2,998,670. Company insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of COR stock traded up $2.84 during trading on Wednesday, hitting $271.32. The company's stock had a trading volume of 1,036,117 shares, compared to its average volume of 1,607,563. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company has a market cap of $52.61 billion, a PE ratio of 38.59, a P/E/G ratio of 1.31 and a beta of 0.51. The business has a fifty day moving average of $251.80 and a 200-day moving average of $240.46. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $271.86.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.81%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.